Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Pain management

Handheld cluster headache device recommended by NICE

GammaCore device

Source: ElectroCore

The gammaCore device has been recommended in draft guidance for the treatment of cluster headaches

An electronic handheld device that can be used to prevent and treat cluster headaches in some patients has been recommended in draft guidance published by the National Institute for Health and Care Excellence (NICE).

The device, which is branded ’gammaCore’ (ElectroCore) works by delivering a small electric current and aims to modify pain signals by stimulating the vagus nerve through the skin of the neck. It can be used to stop pain when the person feels a cluster headache beginning or daily to help prevent cluster headaches.

According to NICE, which published the guidance for public consultation on 5 July 2019, the device is small and portable, and the user only requires brief training.

It is expected that, using gammaCore in addition to standard care (sumatriptan, zolmitriptan and oxygen), could save the NHS £450 per patient in the first year compared to standard care alone.

Meindert Boysen, director of the centre for health technology evaluation at NICE, said “Cluster headaches are excruciatingly painful and debilitating, and can have a huge effect on a person’s life including affecting their ability to work or do normal activities”.

“Many people with the condition don’t get enough pain relief with current treatment options, which are often used off-label and limited by side effects and contraindications.

“The committee heard that, on average, five people per year in the UK end their lives because they are no longer able to live with the pain of cluster headaches.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206775

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.